The ASCO Annual Meeting was held from 4 till 8 June 2021 in a virtual format. During this meeting, immunotherapy arrived in first-line recurrent/metastatic nasopharyngeal carcinoma, adjuvant capecitabine enters prudently the treatment algorithm of nasopharyngeal cancer, results of de-escalation studies in HPV-positive oropharyngeal cancer are promising and forwarding to phase III studies, cabozantinib shows impressive results in later-line radioiodine-refractory differentiated thyroid cancer, and immunotherapy tries to find a place in recurrent/metastatic salivary gland tumours, a tumour type without a uniform standard of care anno 2021. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.

(BELG J MED ONCOL 2021;15(5):226-33)